$MC

Moelis & Company Reports Second Quarter and First Half 2026 Financial Results

Moelis & Co (MC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Moelis & Company Reports Second Quarter and First Half 2026 Financial Results; Declares Regular Quarterly Dividend of $0.65 Per Share • Record second quarter revenues of $409.4 million, up 12% from the prior year period • Record first half revenues of $729.2 million,

Original reporting
Published Jul 29, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 29, 2026, 8:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$MC
Bullish
high confidence
Mentioned
$MC
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$MCBullishMed
01

Why it matters

Traders can update expectations for fee-driven earnings power based on reported revenue growth, margin improvement, and the declared dividend, while monitoring the stated sensitivity to transaction timing.

02

Market read

Fresh quarterly financial prints plus a declared dividend and buyback activity can move valuation and near-term sentiment for MC, with ongoing sensitivity to deal volumes.

03

What to watch

The company notes results can fluctuate materially with transaction timing and size, so near-term earnings visibility may remain limited even with record revenues.

Relevance 7/10Novelty 7/10Timing: after-hours filing of Q2 and first-half 2026 results and dividend declaration

Background

This is an SEC 8-K Item 2.02 with Exhibit 99.1 reporting Moelis second-quarter and first-half 2026 financial results and capital return actions.

Company-level read

Ticker impact

$MCBullishHigh confidence
Context

Moelis reported Q2 2026 revenues of $409.4M (+12% YoY) and GAAP EPS of $0.62, plus a $0.65 quarterly dividend and $64.43 avg buyback price.

Expected impact

Likely modest positive near-term bias as investors price in stronger top-line and EPS plus capital return, though transaction-fee variability remains a risk.

Evidence & confidence

The filing discloses specific quarterly and first-half financial datapoints, margin improvement, and concrete capital actions (dividend declaration and open-market repurchases).

Market effects

Provides a read-through on investment-banking and advisory fee demand, with margin expansion and hiring tied to private credit and debt capital markets.

No explicit regional breakdown beyond Europe hiring plans; limited direct regional signal.

Primarily US-listed company results; global relevance comes from cross-border deal activity and Europe-focused hires.

Counterpoint

Despite revenue growth, first-half GAAP net income attributable to Moelis fell to $87.0M from $91.8M, suggesting earnings quality and tax/one-off items may temper enthusiasm.

Key entities

  • Moelis & Company

    NYSE-listed investment banking and advisory firm reporting Q2 and first-half 2026 results, dividend, and share repurchases.

  • Navid Mahmoodzadegan

    CEO and Co-Founder quoted on client engagement and transaction momentum.

Related articles

$PJTMed

Investment Banking & Brokerage Stocks Q2 In Review: PJT (NYSE:PJT) Vs Peers

Perella Weinberg (PJT) reported flat revenue of $156.5M, beating EPS estimates, with stock up 7.1%. Houlihan Lokey (HLI) saw revenue drop 15.6% to $511M, missing estimates, with stock down 8%. Goldman Sachs (GS) reported $20.34B revenue, up 39.5%, beating estimates, but stock down 4%. Moelis (MC) reported $409.4M revenue, up 12%, beating estimates, with stock up 2.5%.

$SIFYMed

SIFY TECHNOLOGIES LTD (SIFY): Financial results for Q2 2026

SIFY TECHNOLOGIES LTD (SIFY) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 For immediate release Chennai, India DETAILS OF EARNING CALL October 28, 2026| 8:30 AM ET | 06:00 PM IST Participant Dial in: To join: +1- 877-545-0320 (Toll Free in the U.S. or Canada) or +1-973-528-0002 (International) | Access Code: 656813 On the call: Mr. Raju Ve

$GMABHighAI 8/10

Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%

Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.

$FCFMed

First Commonwealth Q3 2026 slides: margin gains counter credit headwinds

First Commonwealth Financial (FCF) reported Q3 2026 earnings with revenue of $143.04M, beating estimates, but EPS of $0.45 missed expectations. Net interest margin expanded to 4.11%, while credit provisions rose to $14.2M. Shares fell 1.86% post-results. Loan growth was modest, and deposit costs declined. Noninterest income remained stable, and the company continued share buybacks.